Against this background, we conducted a pilot study to evaluate the feasibility and safety of symptom-limited CPET and 6MWT in patients with high-risk or relapsed hematologic malignancies, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback